HSBC analyst downgraded AstraZeneca's rating, noting that AstraZeneca trails GSK in stock performance.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
HSBC analyst downgraded AstraZeneca's rating, noting that AstraZeneca trails GSK in stock performance.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Companies like BAE Systems, GSK, AstraZeneca, and HSBC are benefiting from geopolitical tensions, market recoveries, and strong market conditions in Europe.Also in this story
- easyJet soared on the FTSE 250, while GSK losses contributed to the FTSE 100 decline, alongside a rise in Bank of Ireland shares.
- GSK and AstraZeneca are utilizing Manchester as a base for their talent pipeline development and early career scientist recruitment events.
- Market performance update on July 1, 2026, showing mixed results for companies including AstraZeneca, with some rallying and others facing deepening losses in their sugar business.
The entities involved
-
HSBC
British multinational bank
-
AstraZeneca
British-Swedish pharmaceutical company
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- Policybazaar's stock rating was downgraded on September 1, 2026, due to regulatory uncertainty.
- Jefferies Financial Group provided analyst ratings for AstraZeneca stock on June 20, 2026.
- AstraZeneca plans its largest manufacturing investment in Virginia, reported from Cambridge.
- HSBC has issued a rating regarding the stock of Hexaware Technologies.
- HSBC provided a rating upgrade on MGM Resorts International stock, with market consensus suggesting a 'Moderate Buy' rating.
Coverage
Newest first; wire copies grouped- yahoo.comAnalysis-AstraZeneca 'magic' faces rare test after trial failure, share slide